PL2112155T3 - Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania - Google Patents

Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania

Info

Publication number
PL2112155T3
PL2112155T3 PL08155220T PL08155220T PL2112155T3 PL 2112155 T3 PL2112155 T3 PL 2112155T3 PL 08155220 T PL08155220 T PL 08155220T PL 08155220 T PL08155220 T PL 08155220T PL 2112155 T3 PL2112155 T3 PL 2112155T3
Authority
PL
Poland
Prior art keywords
preparation
tetrahydrothieno
cyclopropylcarbonyl
fluorobenzyl
acetoxy
Prior art date
Application number
PL08155220T
Other languages
English (en)
Inventor
Andreas Hotter
Josef Wieser
Arthur Pichler
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of PL2112155T3 publication Critical patent/PL2112155T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL08155220T 2008-04-25 2008-04-25 Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania PL2112155T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08155220A EP2112155B1 (en) 2008-04-25 2008-04-25 Hydrogensulfate salt of 2-acetoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine and its preparation

Publications (1)

Publication Number Publication Date
PL2112155T3 true PL2112155T3 (pl) 2011-03-31

Family

ID=39485072

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08155220T PL2112155T3 (pl) 2008-04-25 2008-04-25 Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania

Country Status (10)

Country Link
EP (2) EP2112155B1 (pl)
CN (1) CN102076699B (pl)
AT (1) ATE482961T1 (pl)
BR (1) BRPI0910616A2 (pl)
CA (1) CA2722248C (pl)
DE (1) DE602008002820D1 (pl)
EA (1) EA017885B1 (pl)
ES (1) ES2353853T3 (pl)
PL (1) PL2112155T3 (pl)
WO (1) WO2009130289A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60135780D1 (de) 2000-12-25 2008-10-23 Daiichi Sankyo Co Ltd Aspirin enthaltende medizinische zusammensetzungen
KR20110045034A (ko) * 2008-08-02 2011-05-03 루난 파마슈티컬 그룹 코퍼레이션 프라수그렐 황산수소염 및 이의 약제학적 조성물 및 용도
SI2398468T1 (sl) 2009-02-17 2017-03-31 Krka, D.D., Novo Mesto Farmacevtske sestave, ki obsegajo prasugrel ali njegove farmacevtsko sprejemljive kislinske adicijske soli in postopek za njihovo pripravo
GB2469883A (en) * 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
EP2360159A1 (de) * 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2377520A1 (de) 2010-03-24 2011-10-19 Ratiopharm GmbH Pharmazeutische Zusammensetzung des Prasugrels
KR101785186B1 (ko) 2010-04-08 2017-10-12 테바 파마슈티컬 인더스트리즈 리미티드 프라수그렐 염의 결정형
CN102675338A (zh) * 2011-03-11 2012-09-19 上海现代制药股份有限公司 微粉化普拉格雷及其药用组合物
CN102838617A (zh) * 2011-06-21 2012-12-26 江苏威凯尔医药科技有限公司 (S)-2-(2-烟酰氧基-6,7-二氢噻吩并[3,2-c]吡啶-5(4H)-基)-2-(2-氯苯基)-乙酸甲酯的多晶型物和药物组合物
CN102838618A (zh) * 2011-06-22 2012-12-26 广东东阳光药业有限公司 一种制备普拉格雷的方法及普拉格雷盐酸盐新晶型
EP2736509B1 (en) 2011-07-28 2015-09-23 Laboratorios Lesvi, S.L. Process for preparing prasugrel
CN102512415B (zh) * 2011-12-16 2013-07-31 山东齐都药业有限公司 一种硫酸氢氯吡格雷药物组合物及制备方法
US8603537B2 (en) * 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
CN102977116B (zh) * 2012-12-24 2014-12-03 天津大学 一种无定形普拉格雷硫酸氢盐及其制备方法
EP2979693A1 (en) * 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising prasugrel or pharmaceutically acceptable salt thereof and process for its preparation
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
CN107814810A (zh) * 2016-09-14 2018-03-20 天津科技大学 一种普拉格雷硫酸氢盐新晶型及其制备方法
CN107915743A (zh) * 2016-10-10 2018-04-17 天津科技大学 一种普拉格雷硫酸氢盐晶型iv及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
KR20090033917A (ko) 2000-07-06 2009-04-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
CA2363053C (en) 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
GB0325603D0 (en) 2003-11-03 2003-12-10 Sandoz Ag Organic compounds
CN101212954A (zh) 2005-05-10 2008-07-02 伊兰制药国际有限公司 纳米粒氯吡格雷制剂
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
EP1940399A2 (en) 2005-08-19 2008-07-09 Eli Lilly & Company Use of par-i/par- 4 inhibitors for treating or preventing vascular diseases
WO2007027454A1 (en) 2005-08-30 2007-03-08 Bristol-Myers Squibb Company Heterocyclic dihydropyrimidine compounds
US20100145053A1 (en) 2006-04-05 2010-06-10 Cadila Healthcare Limited Modified release clopidogrel formulation
TWI392681B (zh) 2006-04-06 2013-04-11 Daiichi Sankyo Co Ltd 高純度普拉格雷及其酸加成鹽之製法

Also Published As

Publication number Publication date
WO2009130289A1 (en) 2009-10-29
ES2353853T3 (es) 2011-03-07
EP2285812A1 (en) 2011-02-23
EA017885B1 (ru) 2013-03-29
EA201001548A1 (ru) 2011-06-30
BRPI0910616A2 (pt) 2019-10-29
EP2112155B1 (en) 2010-09-29
DE602008002820D1 (de) 2010-11-11
ATE482961T1 (de) 2010-10-15
EP2112155A1 (en) 2009-10-28
CN102076699B (zh) 2013-11-13
CA2722248C (en) 2016-06-28
CA2722248A1 (en) 2009-10-29
CN102076699A (zh) 2011-05-25

Similar Documents

Publication Publication Date Title
PL2112155T3 (pl) Wodorosiarczan (VI) 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny i sposób jego otrzymywania
IL212716A0 (en) Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer
MX343274B (es) Inhibidores de la replicacion del vih.
BG108868A (en) Polymorphs of clopidogrel hydrochloride and their use as antithrombic compounds
AP2939A (en) Thieno [2,3-B] pyridine derivatives as viral replication inhibitors
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
IL209229A (en) Salt, hydrate or solvate of 2-fluoro-n-methyl-4- [7- (quinoline-6-yl-methyl) -imidzo [2,1- b] [4,2,1] triazine-2-yl] Benzamide dihydrochloric acid and preparations containing it
CY1115917T1 (el) Νεες κρυσταλλικες πολυμορφες κλοπιδογρελης
IL215074A0 (en) Substituted imidazo[1,2-a]pyridine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
EP2549874A4 (en) SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
WO2011042860A3 (en) New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria
TNSN06311A1 (en) Clopidogrel salt and polymorphic forms thereof
BG109429A (en) A METHOD FOR OBTAINING A CRYSTAL POLYMORPHIC FORMAN FOR INHIBITING TROMBOCYTE AGGREGATION
TNSN06331A1 (en) Polymorphic forms of methyl (+) - (s) -alpha- (2-chlorophenyl) -6, 7-dihydrothieno [3,2-c] pyridine-5 (4h) acetate hydrobromide, clopidrogel hydrobromide
HU0600194D0 (en) Process for producing (s)-(+)-methyl-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetate hidrogen sulfate polimorph i
MX2013015001A (es) Formas solidas y sales de derivados de tetrahidro-pirido-pirimidin a.
EA201290535A1 (ru) Способ получения фармацевтических соединений и промежуточных соединений
WO2008108742A3 (en) Polymorphic forms of clopidogrel hydrobromide
BG109428A (en) METHOD FOR OBTAINING AMORPHIC FORM OF MEDICINES INHIBITION OF THERAPEUTIC AGGREGATION
HUP0600919A3 (en) 7h-thieno[2,3-b]pyridin-6-one derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HU0700809D0 (en) Racemisation process for producing methyl (r,s)-(+)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4h)-acetate hydrogene sulfate intermediate
HU0600706D0 (en) Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidin-4-yl amines, pharmaceutically acceptable salts of them, process for their preparation and pharmaceutical compositions containing the same
PL382311A1 (pl) Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
NZ724713B2 (en) Preparation containing tetracyclic compound at high dose